Publication: Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin.
dc.contributor.author | Sorlozano-Puerto, Antonio | |
dc.contributor.author | Navarro-Mari, Jose Maria | |
dc.contributor.author | Gutierrez-Fernandez, Jose | |
dc.date.accessioned | 2023-01-25T09:43:08Z | |
dc.date.available | 2023-01-25T09:43:08Z | |
dc.date.issued | 2017-01-24 | |
dc.description.abstract | We read with interest the report by Aguilar-Company et al. (1) on two cases of recurrent enteritis due to Campylobacter coli successfully treated with oral fosfomycin-tromethamine. Campylobacter spp. are among the main microorganisms responsible for enteritis and are the principal cause of bacterial diarrhea in our setting, ahead of the genus Salmonella; they are responsible for 44.0% of cases, a percentage that has substantially increased over recent years (2). Although the disease is often mild and self-limiting, it is frequently observed in patients with immunologic alterations and there is growing resistance to macrolides and fluoroquinolones, increasing the risk of a lethal outcome (3). | |
dc.description.version | No | |
dc.identifier.citation | Sorlózano-Puerto A, Navarro-Marí JM, Gutiérrez-Fernández J. Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02317-16. | |
dc.identifier.doi | 10.1128/AAC.02317-16 | |
dc.identifier.essn | 1098-6596 | |
dc.identifier.pmc | PMC5278721 | |
dc.identifier.pmid | 28119317 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278721/pdf | |
dc.identifier.unpaywallURL | https://europepmc.org/articles/pmc5278721?pdf=render | |
dc.identifier.uri | http://hdl.handle.net/10668/10803 | |
dc.issue.number | 2 | |
dc.journal.title | Antimicrobial agents and chemotherapy | |
dc.journal.titleabbreviation | Antimicrob Agents Chemother | |
dc.language.iso | en | |
dc.organization | IBS | |
dc.page.number | 2 | |
dc.provenance | Realizada la curación de contenido 10/03/2025 | |
dc.publisher | American Society for Microbiology | |
dc.pubmedtype | Letter | |
dc.pubmedtype | Comment | |
dc.relation.publisherversion | https://journals.asm.org/doi/10.1128/AAC.02317-16?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Animals | |
dc.subject | Chickens | |
dc.subject | Fosfomycin | |
dc.subject | Campylobacter Infections | |
dc.subject | Campylobacter jejuni | |
dc.subject.decs | Enteritis | |
dc.subject.decs | Diarrea | |
dc.subject.decs | Macrólidos | |
dc.subject.decs | Salmonella | |
dc.subject.decs | Ego | |
dc.subject.decs | Pacientes | |
dc.subject.decs | Campylobacter coli | |
dc.subject.decs | Fluoroquinolonas | |
dc.subject.decs | Fosfomicina | |
dc.subject.mesh | Campylobacter coli | |
dc.subject.mesh | Macrolides | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Bacterial Infections | |
dc.subject.mesh | Diarrhea | |
dc.title | Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin. | |
dc.type | letter to the editor | |
dc.type.hasVersion | VoR | |
dc.volume.number | 61 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format